BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Remon Medical Technologies Ltd. Announces First European Implants Of The Remon(TM) ImPressure(TM), A Wireless Device For Monitoring Pulmonary Artery Pressure In Congestive Heart Failure Patients


10/6/2006 10:29:32 AM

CAESAREA, Israel, October 6 /PRNewswire/ --

- Remon Medical Presents the First European use of its Implantable Hemodynamic Monitor for Home use. The Remon ImPressure(TM) Offers on-Demand, Non-Invasive Self-Monitoring of Pulmonary Artery Pressures by the Patient

Remon Medical Technologies, Inc., a privately held medical device company, today announced the first European use of its implantable hemodynamic monitor. The Remon(TM) ImPressure(TM)offers on-demand, non-invasive, leadless self-monitoring of pulmonary artery pressure by the patient at home. ImPressure(TM) devices were implanted in four patients, at two sites in Germany. In all four cases, pulmonary artery pressure readings were successfully transmitted to the hand-held home monitor and the clinic unit immediately after the implantation and in subsequent follow-ups.

Professor Dr. Uta Hoppe, of the Internal Medicine Department, University of Cologne noted that "After implanting the Remon ImPressure, the hand-held home unit provides the patient with a unique tool for self monitoring. This monitor will be easy for my patients to use at home, and is expected to give early warning of the need for treatment, avoiding hospitalization and deterioration in the patient's condition."

Data from the hand-held monitor can be downloaded to a laptop clinic system, displaying a history of the patient's pulmonary pressure readings. "This graphic display of pulmonary artery pressure waveform will certainly assist in determining optimal treatment for each patient, resulting in better disease management," added Professor Hoppe.

The Remon ImPressure is introduced percutaneously, via a simple vein catheterization procedure, using jugular or femoral access. The miniature device, based on Remon's proprietary acoustic technology, is wireless and leadless. The patient uses a portable battery operated hand-held unit to interrogate the implant. The measurement can be taken at home, or away from home, without any special preparation, and without exposing the patient to radiation.

Professor Dr. Horst Sievert, Director of the CardioVascular Center Frankfurt, Sankt Katharinien, commented: "I was impressed by the simplicity and ease of delivering the ImPressure to the pulmonary artery. The physician's ability to choose between intra-jugular and femoral approaches and the low profile of the delivery system add significantly to the system flexibility."

Hezi Himelfarb, Remon's CEO, said: "We are excited to see our device implanted for the first time in Europe, as part of a trial to meet the requirements for CE mark regulatory approval. Our device demonstrates the inherent value of Remon's unique acoustic communication. We believe that our technology has many other applications that will dramatically impact several areas within medicine".

About Remon Medical

Remon Medical Technologies, Inc. develops and commercializes smart, miniature implants which enable physicians to assess and treat a variety of medical conditions in a non-invasive manner. Remon's enabling technology utilizes wireless communication to exchange energy and data with and between miniature devices placed deep inside the body, in order to monitor a variety of physiological parameters and create therapeutic responses. The company's RemonIBC(TM) - Intra-Body Communication technology allows wireless wakeup of totally dormant implantable devices and communication between several devices implanted inside the body in a totally wireless fashion.

Remon's unique platform has broad applications for patient management, post-operative monitoring, nerve and tissue stimulation, and local drug delivery/release.

Remon is backed by leading global investors, including Concord Ventures, Polaris Venture Partners, Lilly Ventures, KBL Healthcare Ventures, Ofer Hi-Tech Group, Triathlon Medical Ventures, Medica Venture Partners and Guidant Corporation.

For more information about Remon Medical, visit www.RemonMedical.com CONTACT: Hezi Himelfarb CEO Remon Medical Technologies Inc. U.S. Mobile: +1-(201)-658-6383 OUS Mobile: +972-52-249-7044 Hezi.Himelfarb@RemonMedical.com

Remon Medical Technologies inc

CONTACT: CONTACT: Hezi Himelfarb, CEO, Remon Medical Technologies Inc,U.S., Mobile: +1-(201)-658-6383, OUS Mobile:+972-52-249-7044,Hezi.Himelfarb@RemonMedical.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES